Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models

Manabu Onishi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Kentaro Fujii, Koichi Yoshida, Satoshi Inoue, Hiroyuki Michiue, E. Antonio Chiocca, Balveen Kaur, Isao Date

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Integrins are expressed in tumor cells and tumor endothelial cells, and likely play important roles in glioma angiogenesis and invasion. We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an αvβ3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1 and J3T-2. Immunohistochemical staining of cells in culture and brain tumors in rats revealed positive αvβ3 integrin expression in J3T-2 cells and tumor endothelial cells, but not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice harboring J3T-1 tumors was significantly longer than that of control animals (median survival: 57.5 days and 31.8 days, respectively, P

Original languageEnglish
Pages (from-to)162-174
Number of pages13
JournalNeuropathology
Volume33
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Glioma
Neoplasms
Integrins
Endothelial Cells
Nude Rats
Cilengitide
Brain Neoplasms
Cell Culture Techniques
Staining and Labeling

Keywords

  • Angiogenesis
  • Animal model
  • Glioma
  • Integrin
  • Invasion

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. / Onishi, Manabu; Ichikawa, Tomotsugu; Kurozumi, Kazuhiko; Fujii, Kentaro; Yoshida, Koichi; Inoue, Satoshi; Michiue, Hiroyuki; Chiocca, E. Antonio; Kaur, Balveen; Date, Isao.

In: Neuropathology, Vol. 33, No. 2, 04.2013, p. 162-174.

Research output: Contribution to journalArticle

Onishi, Manabu ; Ichikawa, Tomotsugu ; Kurozumi, Kazuhiko ; Fujii, Kentaro ; Yoshida, Koichi ; Inoue, Satoshi ; Michiue, Hiroyuki ; Chiocca, E. Antonio ; Kaur, Balveen ; Date, Isao. / Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. In: Neuropathology. 2013 ; Vol. 33, No. 2. pp. 162-174.
@article{0384e8fdc4a7480b9c7adf9e6921b9ca,
title = "Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models",
abstract = "Integrins are expressed in tumor cells and tumor endothelial cells, and likely play important roles in glioma angiogenesis and invasion. We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an αvβ3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1 and J3T-2. Immunohistochemical staining of cells in culture and brain tumors in rats revealed positive αvβ3 integrin expression in J3T-2 cells and tumor endothelial cells, but not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice harboring J3T-1 tumors was significantly longer than that of control animals (median survival: 57.5 days and 31.8 days, respectively, P",
keywords = "Angiogenesis, Animal model, Glioma, Integrin, Invasion",
author = "Manabu Onishi and Tomotsugu Ichikawa and Kazuhiko Kurozumi and Kentaro Fujii and Koichi Yoshida and Satoshi Inoue and Hiroyuki Michiue and Chiocca, {E. Antonio} and Balveen Kaur and Isao Date",
year = "2013",
month = "4",
doi = "10.1111/j.1440-1789.2012.01344.x",
language = "English",
volume = "33",
pages = "162--174",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models

AU - Onishi, Manabu

AU - Ichikawa, Tomotsugu

AU - Kurozumi, Kazuhiko

AU - Fujii, Kentaro

AU - Yoshida, Koichi

AU - Inoue, Satoshi

AU - Michiue, Hiroyuki

AU - Chiocca, E. Antonio

AU - Kaur, Balveen

AU - Date, Isao

PY - 2013/4

Y1 - 2013/4

N2 - Integrins are expressed in tumor cells and tumor endothelial cells, and likely play important roles in glioma angiogenesis and invasion. We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an αvβ3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1 and J3T-2. Immunohistochemical staining of cells in culture and brain tumors in rats revealed positive αvβ3 integrin expression in J3T-2 cells and tumor endothelial cells, but not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice harboring J3T-1 tumors was significantly longer than that of control animals (median survival: 57.5 days and 31.8 days, respectively, P

AB - Integrins are expressed in tumor cells and tumor endothelial cells, and likely play important roles in glioma angiogenesis and invasion. We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an αvβ3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1 and J3T-2. Immunohistochemical staining of cells in culture and brain tumors in rats revealed positive αvβ3 integrin expression in J3T-2 cells and tumor endothelial cells, but not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice harboring J3T-1 tumors was significantly longer than that of control animals (median survival: 57.5 days and 31.8 days, respectively, P

KW - Angiogenesis

KW - Animal model

KW - Glioma

KW - Integrin

KW - Invasion

UR - http://www.scopus.com/inward/record.url?scp=84875796771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875796771&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1789.2012.01344.x

DO - 10.1111/j.1440-1789.2012.01344.x

M3 - Article

VL - 33

SP - 162

EP - 174

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 2

ER -